Abstract
Background The purpose of this study was to investigate if the addition of liposome bupivacaine (LB) to an interscalene block (ISB) had an effect on the number of patients with surgical or block related complications.Methods This was a single-center retrospective chart view was performed identifying patients who received an ISB from January 1, 2014 through April 26, 2018 at the University of Minnestoa. 1,518 patients were identified who received an ISB (LB =784, non-liposomal bupivacaine =734). Patients were divided into two groups those who did receive liposome bupivacaine in their ISB and those who did not receive liposome bupivacaine in their ISB. Medical records were individually reviewed for surgical procedure, block medications, complications related to the block or surgical procedure, phone calls to the healthcare system for issues related to opioids or pain within 3 and within 30 days, readmissions within 30 days, and emergency room visits for complications within 3 and 30 days.Results There was no significant difference in the number of patients with surgical or anesthetic complications. Only phone calls for pain within 3 days was significantly different. The LB group had 3.2% of patients call compared to 5.6% in the non-liposomal bupivacaine group (aOR=1.71 [95% CI: 1.04-2.87], p=0.036). We found no significant difference in any of the other secondary outcomes.Conclusions The use of LB in an ISB demonstrated no significant difference compared to non-liposomal bupivacaine in numbers of complications, emergency room visits, and readmissions.
Interscalene Block for Analgesia in Orthopedic Treatment of Shoulder Trauma: Single-Dose Liposomal Bupivacaine versus Perineural Catheter
